Nordisk touts Tresiba insulin injection data

Novo Nordisk (NYSE:NVO) said today that data from the Devote clinical trial indicated that its injected insulin, Tresiba, reduced the risk of severe hypoglycemia when compared to insulin glargine.

The trial enrolled more than 7,500 type 2 diabetes patients at high risk of adverse cardiovascular events and treated them for 2 years with either Tresiba or insulin glargine U100. The long term analysis sought to confirm interim data that the Denmark-based company used to support its FDA approval for Tresiba in September last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Nordisk touts Tresiba insulin injection data appeared first on MassDevice.

from MassDevice http://ift.tt/2gLeh0b